Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Memantine ratiopharm
Memantine ratiopharm 5 mg film-coated tablets Memantine ratiopharm 10 mg film-coated tablets Memantine ratiopharm 15 mg film-coated tablets Memantine ratiopharm 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-219507 · Präparat HOS-216379
- The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
- Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
- Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
- There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
- In post-marketing experience, isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-06-30T02:00:00Z · SHA-256 2856d29758189f9df2aa357b2fdf9015aa6903be25b340be22663f9b92f3547f · Passage 40a8dbbfb09e41303893fa5957472859f9e29d9a25779271a527ed7dc5eff4aa · Zeichen 115–1728 im Abschnitt
Wechselwirkungen · Nemdatine
Nemdatine 5 mg film-coated tablets Nemdatine 10 mg film-coated tablets Nemdatine 15 mg film-coated tablets Nemdatine 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-219670 · Präparat HOS-216415
- The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
- Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
- Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
- There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
- In post-marketing experience, isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-01-17T17:10:00Z · SHA-256 99691b7ac39fca34cdc5af4699564ad311ec730ae275553632ea947bd0b78918 · Passage 40a8dbbfb09e41303893fa5957472859f9e29d9a25779271a527ed7dc5eff4aa · Zeichen 115–1728 im Abschnitt
Wechselwirkungen · Nemdatine
Nemdatine 5 mg film-coated tablets Nemdatine 10 mg film-coated tablets Nemdatine 15 mg film-coated tablets Nemdatine 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16
HOS-219686 · Präparat HOS-216415
- The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
- Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
- Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
- There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
- In post-marketing experience, isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-01-17T17:10:00Z · SHA-256 99691b7ac39fca34cdc5af4699564ad311ec730ae275553632ea947bd0b78918 · Passage 794b2778dd469d4cdc594addb61772c33a04675fec9c7a2a6b3782dc9d625ec0 · Zeichen 115–1746 im Abschnitt
Wechselwirkungen · Memantine Merz
Memantine Merz 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-219940 · Präparat HOS-216483
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-20T16:30:00Z · SHA-256 a765c58a722c548e12e7973c87630a1aa54b09c33aba24456e068ca41bcb3238 · Passage 9c05f7ce8beee44b894a02b1db4630303d29ab9b645a12c75d872d0a45bd5723 · Zeichen 115–1745 im Abschnitt
Wechselwirkungen · Memantine Merz
Memantine Merz 5mg/pump actuation, oral solution · Abschnitt 4.5 · PDF-Seite 13
HOS-219954 · Präparat HOS-216483
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-20T16:30:00Z · SHA-256 a765c58a722c548e12e7973c87630a1aa54b09c33aba24456e068ca41bcb3238 · Passage a9269aee6d2442560b843abf7c46a970e78b1908e970d15f553f013784d82108 · Zeichen 115–1727 im Abschnitt
Wechselwirkungen · Memantine Merz
Memantine Merz 5 mg film-coated tablets Memantine Merz 10 mg film-coated tablets Memantine Merz 15 mg film-coated tablets Memantine Merz 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 24
HOS-219969 · Präparat HOS-216483
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-20T16:30:00Z · SHA-256 a765c58a722c548e12e7973c87630a1aa54b09c33aba24456e068ca41bcb3238 · Passage a9269aee6d2442560b843abf7c46a970e78b1908e970d15f553f013784d82108 · Zeichen 115–1727 im Abschnitt
Wechselwirkungen · Memantine Merz
Memantine Merz 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 33
HOS-219984 · Präparat HOS-216483
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-20T16:30:00Z · SHA-256 a765c58a722c548e12e7973c87630a1aa54b09c33aba24456e068ca41bcb3238 · Passage 9c05f7ce8beee44b894a02b1db4630303d29ab9b645a12c75d872d0a45bd5723 · Zeichen 115–1745 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-129263 · Präparat HOS-096703
11
Antimycobacterials
Rifampicin/Dolutegravir Dolutegravir ↓ The dose of dolutegravir is 50 mg twice
AUC ↓ 54% daily when co-administered with
Cmax ↓ 43% rifampicin. As Triumeq is a fixed dose
Cτ ↓ 72% tablet, an additional 50 mg tablet of
(induction of UGT1A1 dolutegravir should be administered,
and CYP3A enzymes) approximately 12 hours after Triumeq
for the duration of the rifampicin co-
administration (a separate preparation of
dolutegravir is available for this dose
adjustment, see section 4.2).
Rifabutin Dolutegravir ↔ No dose adjustment is necessary.
AUC ↓ 5%
Cmax ↑ 16%
Cτ ↓ 30%
(induction of UGT1A1
and CYP3A enzymes)
Anticonvulsants
Carbamazepine/Dolutegravir Dolutegravir ↓ The recommended dose of dolutegravir
AUC ↓ 49% is 50 mg twice daily when co-
Cmax ↓ 33% administered with carbamazepine. As
Cτ ↓ 73% Triumeq is a fixed dose tablet, an
additional 50 mg tablet of dolutegravir
should be administered, approximately
12 hours after Triumeq for the duration
of the carbamazepine co-administration
(a separate preparation of dolutegravir is
available for this dose adjustment, see
section 4.2).
Phenobarbital/Dolutegravir Dolutegravir↓ The recommended dose of dolutegravir
Phenytoin/Dolutegravir (Not studied, decrease is 50 mg twice daily when co-
Oxcarbazepine/Dolutegravir expected due to induction administered with these metabolic
of UGT1A1 and CYP3A inducers. As Triumeq is a fixed dose
enzymes, a similar tablet, an additional 50 mg tablet of
reduction in exposure as dolutegravir should be administered,
observed with approximately 12 hours after Triumeq
carbamazepine is for the duration of the co-administration
expected) with these metabolic inducers (a separate
preparation of dolutegravir is available
for this dose adjustment, see section
4.2).
Antihistamines (histamine H2 receptor antagonists)
Ranitidine Interaction not studied. No dose adjustment necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) histamine (HOS-088516) ranitidine (HOS-085660) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage c667a478669bd5d7bf1481bff4152a60605199708e7c92778db166c77cf6e33c · Zeichen 16252–19999 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 49
HOS-129358 · Präparat HOS-096703
Phenobarbital/Dolutegravir Dolutegravir↓ The recommended dose of dolutegravir
Phenytoin/Dolutegravir (Not studied, decrease should be adjusted when co-
Oxcarbazepine/Dolutegravir expected due to induction administered with these metabolic
of UGT1A1 and CYP3A inducers.
enzymes, a similar
reduction in exposure as Dosing recommendations are provided
observed with in Table 2 (see section 4.2)
carbamazepine is
expected)
Antihistamines (histamine H2 receptor antagonists)
Ranitidine Interaction not studied. No dose adjustment necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) histamine (HOS-088516) ranitidine (HOS-085660) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 377acffb9770a7db982e8e184dd5622d08989e157d6cb396dd8e98806885ed5e · Zeichen 15553–16394 im Abschnitt
Wechselwirkungen · Memantine Accord
Memantine Accord 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-129487 · Präparat HOS-096731
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience, isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-09T10:46:00Z · SHA-256 c76a61ebe494f3a1ef4aca5fd8d6f2a66a21407a16a5c2a27ea4d0aee8198d5d · Passage eecb100e0c463a96285723dcee7ad8631137b4a84f7220b63f1dff0b568e31e0 · Zeichen 115–1746 im Abschnitt
Wechselwirkungen · Memantine Accord
Memantine Accord 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-129512 · Präparat HOS-096731
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience, isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-09T10:46:00Z · SHA-256 c76a61ebe494f3a1ef4aca5fd8d6f2a66a21407a16a5c2a27ea4d0aee8198d5d · Passage eecb100e0c463a96285723dcee7ad8631137b4a84f7220b63f1dff0b568e31e0 · Zeichen 115–1746 im Abschnitt
Wechselwirkungen · Memantine Accord
Memantine Accord 5 mg film-coated tablets Memantine Accord 10 mg film-coated tablets Memantine Accord 15 mg film-coated tablets Memantine Accord 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 22
HOS-129528 · Präparat HOS-096731
• The mode of action suggests that the effects of L-dopa, dopaminergic agonists, and
anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as
memantine. The effects of barbiturates and neuroleptics may be reduced. Concomitant
administration of memantine with the antispasmodic agents, dantrolene or baclofen, can modify
their effects and a dose adjustment may be necessary.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of
pharmacotoxic psychosis. Both compounds are chemically related NMDA-antagonists. The
same may be true for ketamine and dextromethorphan (see also section 4.4). There is one
published case report on a possible risk also for the combination of memantine and phenytoin.
• Other active substances such as cimetidine, ranitidine, procainamide, quinidine, quinine and
nicotine that use the same renal cationic transport system as amantadine may also possibly
interact with memantine leading to a potential risk of increased plasma levels.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when
memantine is co-administered with HCT or any combination with HCT.
• In post-marketing experience, isolated cases with international normalized ratio (INR) increases
have been reported in patients concomitantly treated with warfarin. Although no causal
relationship has been established, close monitoring of prothrombin time or INR is advisable for
patients concomitantly treated with oral anticoagulants.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): baclofen (HOS-089065) ketamine (HOS-109264) cimetidine (HOS-085835) dantrolene (HOS-109261) hydrochlorothiazide (HOS-086937) quinidine (HOS-085593) quinine (HOS-086616) amantadine (HOS-086615) procainamide (HOS-086617) prothrombin (HOS-085093) ranitidine (HOS-085660) dextromethorphan (HOS-109265) nicotine (HOS-109269) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-09T10:46:00Z · SHA-256 c76a61ebe494f3a1ef4aca5fd8d6f2a66a21407a16a5c2a27ea4d0aee8198d5d · Passage fc0684d7a39bc8446563d68227b09a2c6ce28efb4a477059ec95e489deb8d3b4 · Zeichen 115–1728 im Abschnitt
Wechselwirkungen · Quinsair
Quinsair 240 mg nebuliser solution · Abschnitt 4.5 · PDF-Seite 7
HOS-220315 · Präparat HOS-216587
Other relevant information
Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not affected
to any clinically relevant extent when levofloxacin was administered together with the following
active substances: calcium carbonate, digoxin, glibenclamide and ranitidine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) ranitidine (HOS-085660) calcium carbonate (HOS-088370)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-09T11:39:00Z · SHA-256 bb9445a019b9e48c37786cfd826d2b2ea16820e2f76477321feb37ae725b0dd2 · Passage b38d97ee615be5af56d59cd74b74fb6777d2707dcab57200a83b41fe9b0cd1f6 · Zeichen 1298–1599 im Abschnitt
Wechselwirkungen · Rezolsta
REZOLSTA 800 mg/150 mg film-coated tablets REZOLSTA 675 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15–16
HOS-220482 · Präparat HOS-216626
15
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Based on theoretical Co-administration of
considerations bosentan is REZOLSTA and bosentan is not
expected to decrease darunavir recommended.
and/or cobicistat plasma
concentrations.
(CYP3A induction)
REZOLSTA is expected to
increase bosentan plasma
concentrations.
(CYP3A inhibition)
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A inhibitors
Elbasvir/grazoprevir Based on theoretical Concomitant use of REZOLSTA
considerations REZOLSTA may with elbasvir/grazoprevir is
increase the exposure to contraindicated (see section 4.3).
grazoprevir.
(OATP1B and CYP3A inhibition)
Glecaprevir/pibrentasvir Based on theoretical It is not recommended to
considerations REZOLSTA may co-administer REZOLSTA with
increase the exposure to glecaprevir/pibrentasvir.
glecaprevir and pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HMG CO-A REDUCTASE INHIBITORS
Atorvastatin Atorvastatin (10 mg once daily): Concomitant use of a HMG CoA
Fluvastatin atorvastatin AUC ↑ 290% reductase inhibitor and
Pitavastatin atorvastatin Cmax ↑ 319% REZOLSTA may increase
Pravastatin atorvastatin Cmin ND plasma concentrations of the lipid
Rosuvastatin lowering agent, which may lead
Rosuvastatin (10 mg once daily): to adverse events such as
rosuvastatin AUC ↑ 93% myopathy.
rosuvastatin Cmax ↑ 277%
rosuvastatin Cmin ND When administration of
HMG CoA reductase inhibitors
Based on theoretical and REZOLSTA is desired, it is
considerations REZOLSTA is recommended to start with the
expected to increase the plasma lowest dose and titrate up to the
concentrations of fluvastatin, desired clinical effect while
pitavastatin, pravastatin, lovastatin monitoring for safety.
and simvastatin.
(CYP3A inhibition and/or
transport)
Lovastatin Concomitant use of REZOLSTA
Simvastatin with lovastatin and simvastatin is
contraindicated (see section 4.3).
OTHER LIPID MODIFYING AGENTS
Lomitapide Based on theoretical Co-administration is
considerations, REZOLSTA is contraindicated (see section 4.3)
expected to increase the exposure
of lomitapide when
co-administered.
(CYP3A inhibition)
H2-RECEPTOR ANTAGONISTS
Cimetidine Based on theoretical REZOLSTA can be
Famotidine considerations, no mechanistic co-administered with H2-receptor
Nizatidine interaction is expected. antagonists without dose
Ranitidine adjustments.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) nizatidine (HOS-138496) lovastatin (HOS-086157) cimetidine (HOS-085835) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) lomitapide (HOS-086160) simvastatin (HOS-086158) rosuvastatin (HOS-086307) famotidine (HOS-112087) glecaprevir (HOS-086297) fluvastatin (HOS-086305) hepatitis C virus (HOS-108813) lead (HOS-085592) grazoprevir (HOS-108815) ranitidine (HOS-085660) bosentan (HOS-086291) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T17:33:00Z · SHA-256 fd4a09675891eba65ab2ce0a1cb84ffd3afbb1ff64ec7131830fe2eae67d87dc · Passage c3f67dbe242cf0aa97d93ce58f0ae439888400247429b9e172a821fc834fd2d4 · Zeichen 35405–39694 im Abschnitt
Wechselwirkungen · Rezolsta
REZOLSTA 600 mg/90 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 50–51
HOS-220569 · Präparat HOS-216626
50
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Based on theoretical Co-administration of
considerations bosentan is REZOLSTA and bosentan is not
expected to decrease darunavir recommended.
and/or cobicistat plasma
concentrations.
(CYP3A induction)
REZOLSTA is expected to
increase bosentan plasma
concentrations.
(CYP3A inhibition)
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A inhibitors
Elbasvir/grazoprevir Based on theoretical Concomitant use of REZOLSTA
considerations REZOLSTA may with elbasvir/grazoprevir is
increase the exposure to contraindicated (see section 4.3).
grazoprevir.
(OATP1B and CYP3A inhibition)
Glecaprevir/pibrentasvir Based on theoretical It is not recommended to
considerations REZOLSTA may co-administer REZOLSTA with
increase the exposure to glecaprevir/pibrentasvir.
glecaprevir and pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HMG CO-A REDUCTASE INHIBITORS
Atorvastatin Atorvastatin (10 mg once daily): Concomitant use of a HMG CoA
Fluvastatin atorvastatin AUC ↑ 290% reductase inhibitor and
Pitavastatin atorvastatin Cmax ↑ 319% REZOLSTA may increase
Pravastatin atorvastatin Cmin ND plasma concentrations of the lipid
Rosuvastatin lowering agent, which may lead
Rosuvastatin (10 mg once daily): to adverse events such as
rosuvastatin AUC ↑ 93% myopathy.
rosuvastatin Cmax ↑ 277%
rosuvastatin Cmin ND When administration of
HMG CoA reductase inhibitors
Based on theoretical and REZOLSTA is desired, it is
considerations REZOLSTA is recommended to start with the
expected to increase the plasma lowest dose and titrate up to the
concentrations of fluvastatin, desired clinical effect while
pitavastatin, pravastatin, lovastatin monitoring for safety.
and simvastatin.
(CYP3A inhibition and/or
transport)
Lovastatin Concomitant use of REZOLSTA
Simvastatin with lovastatin and simvastatin is
contraindicated (see section 4.3).
OTHER LIPID MODIFYING AGENTS
Lomitapide Based on theoretical Co-administration is
considerations, REZOLSTA is contraindicated (see section 4.3)
expected to increase the exposure
of lomitapide when
co-administered.
(CYP3A inhibition)
H2-RECEPTOR ANTAGONISTS
Cimetidine Based on theoretical REZOLSTA can be
Famotidine considerations, no mechanistic co-administered with H2-receptor
Nizatidine interaction is expected. antagonists without dose
Ranitidine adjustments.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) nizatidine (HOS-138496) lovastatin (HOS-086157) cimetidine (HOS-085835) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) lomitapide (HOS-086160) simvastatin (HOS-086158) rosuvastatin (HOS-086307) famotidine (HOS-112087) glecaprevir (HOS-086297) fluvastatin (HOS-086305) hepatitis C virus (HOS-108813) lead (HOS-085592) grazoprevir (HOS-108815) ranitidine (HOS-085660) bosentan (HOS-086291) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T17:33:00Z · SHA-256 fd4a09675891eba65ab2ce0a1cb84ffd3afbb1ff64ec7131830fe2eae67d87dc · Passage f2840de9604710292b7e3d868ac9eef4d589baf07713ca889cd69fd7d2d7e5ab · Zeichen 34968–39257 im Abschnitt
Wechselwirkungen · Cerdelga
Cerdelga 21 mg hard capsules Cerdelga 84 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-130423 · Präparat HOS-096915
Caution should be used with weak CYP3A inhibitors (e.g., amlodipine, cilostazol, fluvoxamine,
goldenseal, isoniazid, ranitidine, ranolazine) in PMs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cilostazol (HOS-111550) amlodipine (HOS-086287) ranitidine (HOS-085660) fluvoxamine (HOS-085908) ranolazine (HOS-086141) isoniazid (HOS-088590)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-27T15:21:00Z · SHA-256 1c727ba97e10c9a78b07345b037b7efc3b42bce5b1ed72eaf8881cd34d7be69a · Passage b00867563b6da73db72c16276fb50ab9d65a97257e24a6c61ab1cf03e4220ede · Zeichen 4232–4380 im Abschnitt
Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)
Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 11
HOS-130928 · Präparat HOS-096981
Medicinal product Interaction Recommendations concerning
geometric mean changes (%) coadministration
Antacids
Cimetidine (400 mg BID) Voriconazole Cmax ↑ 18% No dose adjustment
[non-specific CYP450 inhibitor Voriconazole AUCτ ↑ 23%
and increases gastric pH]
Omeprazole (40 mg QD)* Omeprazole Cmax ↑ 116% No dose adjustment of
[CYP2C19 inhibitor; Omeprazole AUCτ ↑ 280% voriconazole is recommended.
CYP2C19 and CYP3A4 Voriconazole Cmax ↑ 15%
substrate] Voriconazole AUCτ ↑ 41% When initiating voriconazole in
patients already receiving
Other proton pump inhibitors omeprazole doses of 40 mg or
that are CYP2C19 substrates above, it is recommended that
may also be inhibited by the omeprazole dose be halved.
voriconazole and may result in
increased plasma concentrations
of these medicinal products.
Ranitidine (150 mg BID) Voriconazole Cmax and AUCτ ↔ No dose adjustment
[increases gastric pH]
Antiarrhythmics
Digoxin (0.25 mg QD) Digoxin Cmax ↔ No dose adjustment
[P-gp substrate] Digoxin AUCτ ↔
Quinidine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of quinidine 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Antibacterials
Flucloxacillin Significantly decreased plasma If concomitant administration of
[CYP450 inducer] voriconazole concentrations have voriconazole with flucloxacillin
been reported. cannot be avoided, monitor for
potential loss of voriconazole
effectiveness (e.g., by therapeutic
drug monitoring); increasing the
dose of voriconazole may be
needed.
Macrolide antibiotics No dose adjustment
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) ranitidine (HOS-085660) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-23T14:40:00Z · SHA-256 8f5a567ef9a1f0f0bee27abd2100fc7726dcc5281b72b1f33957fd6bcec22b38 · Passage 6822b84aad1326dff1dc9a9ed79b0e61078c73545483c2557efa2db9dcb6ed82 · Zeichen 2115–4936 im Abschnitt
Wechselwirkungen · Orkambi
Orkambi 100 mg/125 mg film-coated tablets Orkambi 200 mg/125 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-221798 · Präparat HOS-216894
↓ bupropion A higher dose of bupropion may be required
Due to induction of to obtain the desired clinical effect.
CYP2B6 by LUM Lumacaftor/ivacaftor may decrease the
exposure of bupropion, which may reduce its
efficacy.
Corticosteroids, systemic:
methylprednisolone, ↔ LUM, IVA
prednisone
↓ methylprednisolone, A higher dose of these systemic
prednisone corticosteroids may be required to obtain the
Due to induction of desired clinical effect. Lumacaftor/ivacaftor
CYP3A by LUM may decrease the exposures of
methylprednisolone and prednisone, which
may reduce their efficacy.
H2 blockers:
ranitidine ↔ LUM, IVA
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) methylprednisolone (HOS-088374) ranitidine (HOS-085660) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-02T16:33:00Z · SHA-256 d28325937ad45f912a222cdde679794d4a5e9b15e86e82045eef0a8ce9d3f527 · Passage b68d639d72ee7be13d4157e4a63be6610ef63c79fbb800a3bea9f7c508132cbd · Zeichen 19455–20680 im Abschnitt
Wechselwirkungen · Orkambi
Orkambi 100 mg/125 mg film-coated tablets Orkambi 200 mg/125 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-221799 · Präparat HOS-216894
↑ or ↓ ranitidine Dose adjustment of ranitidine may be
Due to potential required to obtain the desired clinical effect.
induction or inhibition Lumacaftor/ivacaftor may alter the exposure
of P-gp of ranitidine.
Oral hypoglycemics:
repaglinide ↔ LUM, IVA
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranitidine (HOS-085660) repaglinide (HOS-086935)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-02T16:33:00Z · SHA-256 d28325937ad45f912a222cdde679794d4a5e9b15e86e82045eef0a8ce9d3f527 · Passage bcb82cf010e24110261dc2037e5d39fc824a88b0bd601b1181c6ade66994e6d7 · Zeichen 20717–21156 im Abschnitt
Wechselwirkungen · Orkambi
Orkambi 75 mg/94 mg granules in sachet Orkambi 100 mg/125 mg granules in sachet Orkambi 150 mg/188 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 40–41
HOS-221877 · Präparat HOS-216894
40
Concomitant
medicinal product
class:
Active substance name Effect Clinical comment
↓ bupropion A higher dose of bupropion may be
Due to induction of required to obtain the desired clinical
CYP2B6 by LUM effect. Lumacaftor/ivacaftor may decrease
the exposure of bupropion, which may
reduce its efficacy.
Corticosteroids, systemic:
methylprednisolone, ↔ LUM, IVA
prednisone
↓ methylprednisolone, A higher dose of these systemic
prednisone corticosteroids may be required to obtain
Due to induction of the desired clinical effect.
CYP3A by LUM Lumacaftor/ivacaftor may decrease the
exposures of methylprednisolone and
prednisone, which may reduce their
efficacy.
H2 blockers:
ranitidine ↔ LUM, IVA
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) methylprednisolone (HOS-088374) ranitidine (HOS-085660) prednisone (HOS-084526)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-02T16:33:00Z · SHA-256 d28325937ad45f912a222cdde679794d4a5e9b15e86e82045eef0a8ce9d3f527 · Passage beda93d3f767190c47662c2856fb21c9b16a991971a96aef36e910e4c045f256 · Zeichen 19564–20987 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.